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Adult living donor liver transplantations (ALDLTs) across the ABO blood group barrier have been reported in Asia, North
Americas,andEurope,butnotyet inGermany. Severalstrategieshavebeenestablishedtoovercomethedetrimentaleﬀectsthatare
attachedwithsuchadisparitybetweendonorandhost,butnogoldstandardhasyetemerged.Here,wepresenttheﬁrstexperiences
with three ABO-incompatible adult living donor liver transplantations in Germany applying diﬀerent immunosuppressive
strategies. Four patient-donor couples were considered for ABO-incompatible ALDLT. In these patients, resident ABO blood
group antibodies (isoagglutinins) were depleted by plasmapheresis or immunoadsorption and replenishment was inhibited by
splenectomy and/or B-cell-targeted immunosuppression. Despite diﬀerent treatments ALDLT could safely be performed in three
patients and all patients had good initial graft function without signs for antibody-mediated rejection (AMR). Two patients
had long-term graft survival with stable graft function. We thus propose the feasibility of ABO-incompatible ALDLT with these
protocols and advocate further expansion of ABO incompatible ALDLT in multicenter trials to improve eﬃcacy and safety.
Copyright © 2009 Armin D. Goralczyk et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Adult-to-adult living donor liver transplantation (ALDLT)
has been established as an excellent treatment method
for patients with end-stage liver disease and has achieved
exponential growth, especially in Asia [1–4]. Graft and
patient survival now are currently equal to those from
cadaveric transplantation [4].
However, some patients who have otherwise suitable
living donors are not transplanted because of ABO blood
group incompatibility. In the 1960s, it was shown that
transplantation of solid organs, especially kidneys, across the
blood group barrier is associated with hyperacute rejection
and reduced graft survival [5–8]. Therefore, in most coun-
tries, ABO incompatible liver transplantation was generally
only accepted for cases of immediate need and unavailability
of a compatible graft. Interestingly, early reports of blood
group incompatible liver transplantation have shown that a
surprisingly large number of grafts were successful, and it
has thus been suggested that the liver may be less prone to
hyperacute rejection than other solid organs [9, 10].
Since graft survival was still unacceptably low, new ther-
apeutic strategies to ameliorate ABO-incompatible ALDLT
were necessary. In the 1990s, these methods were investi-
gated, mainly in Asia due to the shortage of deceased donors
in these countries and the frequent blood group mismatch
betweenlivingdonorandrecipient[11].Withthenewstrate-
gies, survival has improved considerably and has reached
70% at three years in the latest cohort [12]. Recently, some
authors even report similar outcomes of ABO-incompatible
ALDLT as compared to compatible ALDLT [13, 14]. ABO-
incompatible ALDLT has subsequently gained acceptance
in Europe, namely, in Sweden [15, 16] and Belgium
[17].2 Journal of Transplantation
Table 1: Clinical characteristics of recipients. HCC: hepatocellular carcinoma; HCV: hepatitis C virus.
Case Sex Age at ALDLT Diagnosis and indication for ALDLT Child-Pugh status ABO donor-recipient match
1 F 61 bile duct carcinoma A A2 → O
2 M 44 alcoholic cirrhosis C B → O
3 M 51 cholangiocellular carcinoma A A2B → O
4 M 48 HCC in HCV cirrhosis B A2B → B
Since the recipient is (by deﬁnition) presensitized, the
recognition of blood group antigens by preformed recipient
isoagglutinins and its detrimental consequences remain the
central problem of ABO-incompatible transplantation [7,
18]. Unlike in kidney and heart transplantation, hyperacute
rejection, especially against MHC-class-I antigens, is rarely
observed clinically in liver transplantation [19]. Antibody-
mediated rejection (AMR) may still be present, but it usually
manifests within 2 to 4 weeks after transplantation [19]. In
AMR, the preformed isoagglutinins bind to the graft vas-
culature, resulting in complement activation, migration of
neutrophils, vessel damage, diﬀuse intravascular thrombosis,
and consequent activation of the ﬁbrinolytic system with
hemorrhagic necrosis of the graft [19]. In addition to AMR,
a high incidence of hepatic artery and biliary complications
can be found in patients receiving an ABO-incompatible
allograft [11, 20]. It has been suggested that this also may be
due to immunologic injury, since blood group antigens can
also be found on bile duct epithelium [20].
In most clinical studies, two main strategies to reduce
antibody-mediated complications have been tested in com-
bination. First, preformed isoagglutinins in the recipient
are reduced before transplantation by apheresis [11, 21, 22]
or immunoadsorption [17, 23, 24]. Second, restoration of
isoagglutinins by plasma cells is suppressed by splenectomy,
reinforced immunosuppression [11], or by speciﬁcally inter-
fering with the maturation [17, 21, 25–28]o ra c t i v a t i o n
[29, 30] of B cells.
Here, we report our experiences with ABO incompatible
ALDLT from a single center in Germany applying diﬀerent
aforementioned strategies. We wish to present our practical
experience, including heterogenic results to the transplant
community to show that this strategy is feasible and merits
further expansion.
2. Patientsand Methods
2.1. Patients and Donors. This case series includes four
patients, of which three underwent ALDLT between June
2001 and September 2007. Clinical characteristics of the
patients and donor-recipient blood group match are shown
in Table 1.
All four patients had either end-stage liver disease or
malignant disease of the liver without the possibility of
complete resection, while extrahepatic tumor spreading
was excluded by intense staging procedures. Patients were
evaluated for standard liver transplantation and placed on
the waiting list. As a standard practice of our institution, the
patientswereextensivelyinformedaboutthepossibilitiesand
risks of ALDLT. We were then contacted by the patients and
a possible donor on their own behalf to initiate evaluation
forALDLT.Althoughbloodgroupincompatibilitywasfound
earlyin theevaluationprocess, wecontinued evaluation after
informed consent due to disease severity. In all four patient-
couples, recipient and donor were found medically suitable,
while the interdisciplinary ethics committee on living donor
liver transplantation found no contraindications according
to German transplantation law. Consecutively, ALDLT was
performed.
2.2. Blood Group Typing and Antibody Titers. Red blood cell
group was determined with commercially available antisera
according to standard immunohematologic techniques. The
Anti-A1, -A2, and -B antibodies were determined with direct
and indirect isoagglutination assays. Test erythrocytes were
suspended in serial doubling dilutions of recipient serum,
centrifuged, and analyzed for agglutination. This assay was
deﬁned as representing immunoglobulin (Ig) M activity.
Specimens were then incubated at 37
◦Cf o r3 0m i n u t e s
and washed with normal saline, and antihuman globulin
(Coombs) antiserum was added. The specimen was then
centrifugedandanalyzedforagglutination.Thisantiglobulin
assay was deﬁned as representing IgG activity. By standard
redcellagglutinationreadings,themostdiluteunequivocally
positive reaction was deﬁned as the anti-A or -B antibody
titer value in each assay.
2.3. Perioperative Plasmapheresis. In all patients, plasma-
pheresis was used to reduce isoagglutinin titers to 1 : 16
or lower before and after ALDLT. A standard apheresis
system was used for antibody depletion. Isoagglutinin titers
were measured before plasmapheresis, after plasmapheresis,
and on the following day to assess the eﬃcacy of plasma-
pheresis and the need for additional ﬁltration. In patient 3
immunoadsorption (IA) was also used to reduce antibody
titers. The same standard apheresis system, although not
speciﬁcally designed for column treatments, could easily be
adjusted for this purpose. Plasma was recirculated through
blood group A/B carbohydrate antigen columns (Glycosorb,
Glycorex AB, Lund, Sweden) and then retransfused to the
patient. The method has been described in detail by Kumlien
and colleagues [23].
2.4. Immunosuppression. The immunosuppressive regimens
used are very heterogenic due to the long-time period
over which these four ABO-incompatible ALDLTs were
performed. An overview of the patients’ immunosuppressiveJournal of Transplantation 3
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Figure 1: Immunosuppressive regimens of patients 1, 2, and 4 (panels (a)–(c), resp.) from the day of ﬁrst preoperative treatment
until postoperative day 20. Arrows indicate plasmapheresis or immunoadsorption; grey, green, and khaki colored areas correspond to
maintenance therapy with prednisolone, tacrolimus, and adjuvant immunosuppression, respectively; blue and red area corresponds to
induction treatment with daclizumab (100mg at ALDLT and 50mg on the seventh postoperative day) or antithymocyte globulin (1.5mg
per kilogram body weight) for 10 days and methylprednisolone (500mg), respectively. PP: plasmapheresis; OP: relaparotomy.
regimenisshowninFigure 1.Thestandardimmunosuppres-
sive regimen consisted of induction therapy with antibodies
directed against white blood cell epitopes, maintenance ther-
apy with corticosteroids and tacrolimus (Prograf, Astellas
Pharma, Tokyo, Japan), and adjuvant immunosuppression
with either sirolimus (Wyeth, Madison, USA) or mycophe-
nolate mofetil (CellCept, Roche Pharmaceuticals, Basel,
Switzerland).
Therapy with steroids was initiated at surgery intra-
operatively (500mg methylprednisolone) and continued at
1mg/kg body weight prednisolone tapered by 5 or 2.5mg
every two days until a maintenance dose of 7.5mg was
reached. In the ﬁrst two patients, therapy with tacrolimus
was started as a preemptive immunosuppression three days
before ALDLT at half the standard dose (0.05mg/kg body
weight), continued after ALDLT at full dose (0.1mg/kg body
weight), and adjusted to achieve a trough plasma level of 8–
10µg per liter. In the other two patients, standard immuno-
suppressive protocol at our institution had changed to a
tacrolimus sparing regimen to ameliorate the detrimental
eﬀects of tacrolimus on renal function. Tacrolimus was
administered on the fourth postoperative day, starting with4 Journal of Transplantation
a dose of 0.01mg/kg body weight per day and increasing the
daily dose by 1-2mg according to renal function to achieve a
trough plasma level of 8–10µgp e rl i t e r .
In the ﬁrst two patients (Figures 1(a) and 1(b)), splenec-
tomy was performed to reduce resident B cells in the
recipient before implantation of the graft. At the time of
transplantation and on the seventh postoperative day, the
interleukin (IL)-2 receptor antagonist daclizumab (Zenapax,
Roche Pharmaceuticals, Basel, Switzerland) was infused
at 100mg and 50mg, respectively, for the induction of
immunosuppression. As an additional immunosuppressant,
sirolimus was administered at 5mg per day.
Thethirdpatientwastreatedwithrituximab(MabThera,
Roche Pharmaceuticals, Basel, Switzerland) at 375mg per
square meter body surface only once, after extrahepatic
spreadofmalignantdiseasehadbeenexcludedbyexplorative
laparotomy. Mycophenolate mofetil was administered for
adjuvantimmunosuppressionat1gevery12hoursstarting5
days before planned ALDLT. Since the patient was eventually
not transplanted (see below results), he received neither
steroids nor tacrolimus.
The fourth patient (Figure 1(c))r e c e i v e d1 . 5 m gp e r
kilogram body weight antithymocyte globulin (ATG, Thy-
moglobulin, Genzyme Corporation, Cambridge, USA) every
24 hours for 10 days starting on the day of transplantation.
Mycophenolate mofetil was given at 1g every 12 hours
starting 5 days before transplantation. No splenectomy was
performed in the last two patients (patients 3 and 4).
3. Results
3.1. Isoagglutinin Titers. In all patients except patient 3,
isoagglutinin titers could be lowered below 1 : 16 by two
apheresis sessions before ALDLT (see Figure 2(a)). In patient
3,apheresisandimmunoadsorptionhadnolong-termeﬀect.
Although isoagglutinins could eﬀectively be depleted by
plasmapheresis and immunoadsoption (comparing isoag-
glutinintitersmeasuredbeforeanddirectlyafterthesession),
an immediate rebound eﬀect occurred overnight; because
of this unusual course and double ABO-incompatibility, we
decided against ALDLT after eight unsuccessful treatments.
In the ﬁrst 30 days after ALDLT, isoagglutinin titers
remained below 1 : 16 without further treatment in the
ﬁrst two patients. Rising titer levels above the predeﬁned
threshold of 1 : 16 made repeated plasmapheresis necessary
in patient 4. We decided against further treatment after the
fourth session because he had stable graft function without
signs of rejection. Long-term titer levels remained stable in
allthree transplanted patients withoutfurther treatment(see
Figure 2(b)).
3.2. Surgery and Graft Function. Donor hepatectomy and
transplantation was uneventful in all three donor-recipient
couples. Serious adverse events or complications were not
observedinanyofthedonors.Initialliverfunctiontestsindi-
cated good graft function in all three transplanted patients.
3.3. Adverse Events. We observed one febrile nonhemolytic
transfusion reaction at the ﬁrst plasmapheresis session of
patient 3 (patient ﬁnally not-transplanted). Plasmapheresis
was stopped immediately and the symptoms resolved within
12 hours. No other adverse events associated with plasma-
pheresis occurred in any of the patients.
3.4. Complications and Follow-Up. In patient 1, no compli-
cations were observed and the patient was discharged from
the hospital six weeks after ALDLT. One year after ALDLT
she had good liver function without signs for rejection or
dysfunction of the graft.
In the second patient, who suﬀered from decompensated
liver cirrhosis stage Child C, a necrosis of the biliary duct
evolved and relaparotomy was performed on the 15th post-
operative day. He subsequently had severe biliary peritonitis
with septic shock. Repeated infection and septic multiorgan
failure including impaired liver function made long-term
treatment in the critical care unit necessary, and the patient
died on the 110th postoperative day. Repeated liver biopsies
and the bile duct specimen showed no signs of antibody or
complement deposit.
Patient 4 had no in-hospital complications and was
discharged on the 55th postoperative day. Subsequently, he
had cholestasis due to anastomotic stricture and endoscopic
stent placement was necessary. Cholestasis resolved and
bilirubin returned to the normal range. He is alive with good
liver function more than one year after ALDLT.
In all three patients, AMR was excluded histologically
by allograft biopsies taken at diﬀerent time points and, in
patient 2, at autopsy. Standard methods for light microscopy
and immunohistochemistry did not reveal signs of antibody
or cell mediated rejection, that is, deposition of immunglob-
ulins or complement [19].
4. Discussion
Here we describe successful ABO-incompatible ALDLT in
three patients applying diﬀerent protocols, including pre-
and posttransplant apheresis, reinforced immunosuppres-
sion, and/or splenectomy, without any occurrence of AMR
while concurrently presenting the problems and challenges
of the management of such patients.
The largest cohort of patients undergoing ABO-
incompatible ALDLT has been reported by Egawa and
colleagues [12]. In 136 patients registered by the Japan Study
Group for ABO-incompatible transplantation he could show
a signiﬁcant decrease of AMR and increase of survival
between2000and2006owingtoimprovedimmunosuppres-
sive treatment and complication management.
Although we were aware of the increased risks associated
with ABO incompatibility, we decided to provide ABO-
incompatible ALDLT to patients with immediate need for
an allograft, which was not adequately reﬂected by the
standard allocation procedure. Especially patients suﬀering
from malignant tumors of the liver may not receive a
liver graft within the standard allocation procedure because
of their suboptimal prognosis compared to patients with
cirrhosis. If the patient and the potential donor are informed
about the prognosis and risks of ALDLT under the given
circumstances, we evaluated all patients in need for a liverJournal of Transplantation 5
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Figure 2: Perioperative isoagglutinin titers (early phase, panel (a); late phase, panel (b)). Inverse antibody titers of type Anti-A1, -A2, and B
are shown in dark blue, light blue, and green, respectively, on a logarithmic scale. The time scale indicates days after transplant (patients 1,
2, and 4) or days post surgery (patient 3). IA: immunoadsorption; PP: plasmapheresis; RIT: rituximab).
graft and transplantation was performed only because no
other potential ABO-compatible living donor or deceased
donor was available.
Under beneﬁcial conditions ABO incompatible ALDLT
has been conducted without special treatment, but this is
associated with an increased risk of AMR [31]. We thus felt
obliged to treat our ﬁrst two patients according to a protocol
that included repeated plasmapheresis, splenectomy, and
reinforced immunosuppression [11]. The ﬁrst patient we
transplanted applying these strategies had unconstrained
graft function and an uncomplicated course without any
signsofrejection.Long-termmonitoringoftheisoagglutinin
titers showed stable low titers after two preoperative aphere-
sis sessions.
Patient 2 underwent the same protocol but died three
months after ALDLT. The necrosis of the biliary duct may
possibly be due to technical failure but the patient suﬀered
from decompensated alcoholic liver cirrhosis and was in
critical condition before ALDLT. Bile duct necrosis due to
ABO incompatibility is unlikely since no signs for AMR was
seen in liver biopsies and in the bile duct specimen. But the
subsequent clinical course may also be attributed to ABO-
incompatible ALDLT. He suﬀered from recurrent and severe
systemic infection, which ﬁnally led to septic multiorgan
failure and death. It has been recognized that splenec-
tomy and plasmapheresis in combination with reinforced
immunosuppression may lead to overimmunosuppression
and may make patients prone to severe systemic infection
[11, 17].
Inlightofthis,wedecidedtochangeourprotocoltomin-
imize morbidity related to immunosuppression. Recently,
rituximab, a monoclonal humanized antibody against the
target CD20, has been applied for ABO-incompatible kidney
[24, 25, 32, 33] and liver transplantation [21, 27, 34]i nl i e u
of splenectomy. Patient 3 was thus treated with rituximab
after extrahepatic spread of malignant disease had been
excluded. As an additional immunosuppression, we utilized
mycophenolic acid instead of sirolimus because it may be
more eﬀective in inhibiting expansion of the B cell pool
[35, 36]. Despite repeated plasmapheresis and immunoad-
sorbtion, isoagglutinin titers could not be reduced below the
target level for ALDLT, because after each session the patient
experienced a rapid rebound of isoagglutinin titers. This
phenomenon has also been described before [24, 37], but
the exact mechanism remains to be elucidated. Therefore,
we ﬁnally decided against transplantation in the face of
donor risk and increased risk of graft failure. Unfortunately,
no blood group compatible graft could be allocated to this
patientwithinthenextthreemonthsandthepatientsuﬀered
from extrahepatic spread of malignant disease.
In our last patient, we used ATG for the induction of
immunosuppression. ATG interferes with T-cell dependent
activation of alloreactive B-cells by removing CD4+ T-
cell help; and it has been shown to trigger apoptosis not
only in T-cells but also in B-cells [29]a n dm a yt h u sb e
more eﬀective than rituximab. Hence, ATG has been used
eﬀectively to treat AMR [38] and for induction in ABO-
incompatiblekidneytransplantation[30].Inourlastpatient,
we applied a treatmentregimen of 1.5mg perkg body weight
starting at ALDLT and continued until postoperative day
ten, a protocol that has been evaluated for living donor
kidney transplantation by Gloor et al. [30]. In this patient,
preoperative isoagglutinin titers were lowered successful, but
after ALDLT titers increased steadily without clinical signs of
rejection or mitigation of liver function. Eﬀective reduction
of titers was only sustained by repeated plasmapheresis. After
four plasmapheresis sessions, we decided against further
treatment because under a favorable donor-recipient blood
group combination, that is, mismatches for donor blood
group A2 or B [39–41], high pre- and postoperative titer
levels may be tolerated without increasing AMR or graft
loss [15, 16]. Subsequently no AMR or alteration of graftJournal of Transplantation 7
function was seen in this patient, although the relevant titer
(A2) remained elevated for almost half a year before sponta-
neouslydecliningbelowpretransplantlevel(seeFigure 2(b)).
A similar spontaneous decline or stable reduction below
pretransplant levels could also be observed in the other
two patients; this has also been reported by other authors,
suggesting graft accommodation or even tolerance [17, 42].
Deletion and/or anergy have been proposed as possible
mechanisms, but adsorbtion of antibodies by graft antigen
may also be possible.
Optimal treatment of patients after ALDLT should inc-
lude triple immunosuppression (i.e., tacrolimus, mycophe-
nolat mofetil, and prednisolone), pre- and postoperative
plasmapheresis or immunoadsorbtion targeting isoagglu-
tinin titers of 1 : 16 or lower, and induction with rituximab
or ATG. We do not think that splenectomy and portal vein or
hepatic artery infusion is necessary.
5. Conclusion
We have successfully performed three ABO-incompatible
ALDLT with diﬀerent protocols. Protocols were changed
because the three ALDLTs were performed over a period of
six years and there have been many changes in the immuno-
suppressive treatment after ABO-incompatible ALDLT. At
ﬁrst sight this heterogeneity may limit generalizability of
our ﬁndings but also may provide new insight into the
possibilities and limitations of these diﬀerent protocols.
Despite diﬀerences in treatment all patients had good initial
graft function and no signs of rejection after ALDLT and
two of the three patients had a long-term patient and graft
survival. Indeed, further improvement is warranted and
the diﬀerent strategies should be evaluated in multicenter
studies to assess their eﬃcacy and safety. Nonetheless, ABO
incompatibleALDLTshouldbeoﬀeredtoallpatientsincases
of immediate need for an allograft without the possibility to
allocate a blood group compatible organ.
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